Literature DB >> 21138882

Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?

Geoffrey R Connors1, Lisa Christopher-Stine, Chester V Oddis, Sonye K Danoff.   

Abstract

Interstitial lung disease is commonly associated with the autoimmune inflammatory myopathies dermatomyositis and polymyositis and accounts for significant morbidity and mortality in these conditions. In the 35 years since the association between inflammatory myopathy and interstitial lung disease was initially described, there has been progress in diagnosing and treating this dis-order. Nevertheless, there remains much about pathogenesis and therapeutics to be learned. This review examines the changes in the understanding of this complex condition, highlighting recent advances and areas deserving of further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138882     DOI: 10.1378/chest.10-0180

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  100 in total

1.  Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.

Authors:  Isabela Bruna Pires Borges; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2018-12-05       Impact factor: 2.631

Review 2.  Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review.

Authors:  Yongpeng Ge; Qinglin Peng; Sigong Zhang; Hang Zhou; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2014-11-01       Impact factor: 2.980

3.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  Occupational exposure in patients with the antisynthetase syndrome.

Authors:  Ane Labirua-Iturburu; Albert Selva-O'Callaghan; Jan-Paul Zock; Ramon Orriols; Xavier Martínez-Gómez; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

5.  Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry.

Authors:  Kevin R Flaherty; Dinesh Khanna
Journal:  Thorax       Date:  2014-01-06       Impact factor: 9.139

Review 6.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

7.  [Progressive respiratory failure and weakness in a 61-year-old woman].

Authors:  M Mahmud; U Schnoor; O M Steinmetz
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743

Review 8.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 9.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 10.  Selected aspects of the current management of myositis.

Authors:  James Lilleker; Sean Murphy; Robert Cooper
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-19       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.